Chang Yoon Jung, Cho Seungyeon, Joo Jungnam, Ryu Kum Hei, Lee Sangwon, Cho Juhee, Lim Myong Cheol, Jung So-Youn, Han Jai Hong, Lee Eun Sook, Kong Sun-Young
Division of Cancer Control & Policy, National Cancer Control Institute, National Cancer Center, Goyang 10408, Korea.
Department of Cancer Control and Policy, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, Korea.
J Pers Med. 2022 May 18;12(5):818. doi: 10.3390/jpm12050818.
We aimed to understand the decision-making process related to the willingness to undergo BRCA1/2 genetic testing, risk-reducing salpingo-oophorectomy (RRSO), or risk-reducing mastectomy (RRM) among the general public, cancer patients, and healthcare professionals in South Korea. In total, 3444 individuals (1496 from the general public, 1500 cancer patients, 108 clinicians, and 340 researchers) completed a survey addressing genetic testing and related risk management options in a hypothetical scenario. Differences in intent and associated factors for undergoing the above procedures or sharing test results were analyzed. Overall, 67% of participants were willing to undergo BRCA1/2 testing, with proportions of the general public (58%), cancer patients (70%), clinicians (88%), and researchers (90%). The willingness to undergo RRSO was highest among clinicians (58%), followed by among patients (38%), the general public (33%), and researchers (32%) (p < 0.001). Gender, age, education level, and household income were associated with willingness to undergo genetic testing, RRM, and RRSO (p < 0.05). The intent for undergo genetic testing, RRM, and RRSO were affected by many factors. Finally, 69% of the general public intended to share information with family, while this percentage was 92%, 91%, and 94% for patients, clinicians, and researchers, respectively (p < 0.05). These results highlight the requirement for developing targeted educational materials and counseling strategies for facilitating informed decision making.
我们旨在了解韩国普通公众、癌症患者及医疗保健专业人员中与接受BRCA1/2基因检测、降低风险的输卵管卵巢切除术（RRSO）或降低风险的乳房切除术（RRM）意愿相关的决策过程。共有3444人（1496名普通公众、1500名癌症患者、108名临床医生和340名研究人员）完成了一项针对假设情景下基因检测及相关风险管理选项的调查。分析了接受上述手术或分享检测结果的意愿及相关因素的差异。总体而言，67%的参与者愿意接受BRCA1/2检测，其中普通公众的比例为58%，癌症患者为70%，临床医生为88%，研究人员为90%。临床医生中接受RRSO的意愿最高（58%），其次是患者（38%）、普通公众（33%）和研究人员（32%）（p<0.001）。性别、年龄、教育水平和家庭收入与接受基因检测、RRM和RRSO的意愿相关（p<0.05）。接受基因检测、RRM和RRSO的意愿受多种因素影响。最后，69%的普通公众打算与家人分享信息，而患者、临床医生和研究人员的这一比例分别为92%、91%和94%（p<0.05）。这些结果凸显了开发有针对性的教育材料和咨询策略以促进明智决策的必要性。
